Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials

To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms. adjunctive aripiprazole vs. adju...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-08, Vol.8 (8), p.e70179
Main Authors: Li, Xianbin, Tang, Yilang, Wang, Chuanyue
Format: Article
Language:English
Subjects:
Anesthesia
Antipsychotic Agents - adverse effects
Antipsychotics
Archives & records
Aripiprazole
Breast cancer
Care and treatment
Clinical trials
Collaboration
Confidence intervals
Dopamine
Dosage and administration
Drug dosages
Drug therapy
Extrapyramidal system
Fatigue
Headache
Health aspects
Herbal medicine
Humans
Hyperprolactinemia
Hyperprolactinemia - chemically induced
Hyperprolactinemia - drug therapy
Insomnia
Medicine
Mental disorders
Meta-analysis
Patients
Pharmacology
Piperazines - adverse effects
Piperazines - therapeutic use
Placebos
Prolactin
Psychiatry
Psychosis
Psychotropic drugs
Quinolones - adverse effects
Quinolones - therapeutic use
Randomization
Randomized Controlled Trials as Topic
Risk factors
Schizophrenia
Sleep disorders
Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms. adjunctive aripiprazole vs. adjunctive placebo. adverse events and efficacy of treatment. randomized controlled trials. Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo) met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed) -0.05 to 0.04 (95% confidence interval -0.13 to 0.16); I(2) =0% to 68%, P=0.20 to 0.70). However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I(2) =43%, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0070179